103 related articles for article (PubMed ID: 12490312)
1. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Loktionov A; Watson MA; Stebbings WS; Speakman CT; Bingham SA
Cancer Lett; 2003 Jan; 189(2):189-96. PubMed ID: 12490312
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.
Smolarz B; Blasiak J; Kulig A; Romanowicz-Makowska H; Dziki A; Ulanska J; Pander B; Szewczyk T
J Exp Clin Cancer Res; 2001 Jun; 20(2):247-52. PubMed ID: 11484982
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor -1 gene 4G/5G polymorphism in patients with breast cancer.
Eroglu A; Ulu A; Cam R; Akar N
J BUON; 2006; 11(4):481-4. PubMed ID: 17309181
[TBL] [Abstract][Full Text] [Related]
4. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S
Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
[TBL] [Abstract][Full Text] [Related]
5. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.
Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS
Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080
[TBL] [Abstract][Full Text] [Related]
6. 4G/5G polymorphism of PAI-1 gene promoter and fibrinolytic capacity in patients with deep vein thrombosis.
Sartori MT; Wiman B; Vettore S; Dazzi F; Girolami A; Patrassi GM
Thromb Haemost; 1998 Dec; 80(6):956-60. PubMed ID: 9869167
[TBL] [Abstract][Full Text] [Related]
7. The plasminogen activator inhibitor (PAI-1) 4G/5G promoter polymorphism and PAI-1 levels in ischemic stroke. A case-control study.
van Goor ML; Gómez García E; Leebeek F; Brouwers GJ; Koudstaal P; Dippel D
Thromb Haemost; 2005 Jan; 93(1):92-6. PubMed ID: 15630497
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
Arch Med Res; 2013 Jan; 44(1):39-45. PubMed ID: 23291383
[TBL] [Abstract][Full Text] [Related]
9. Tissue plasminogen activator and plasminogen activator inhibitor-1 gene polymorphisms in patients with chronic periodontitis.
Gürkan A; Emingil G; Saygan BH; Cinarcik S; Atilla G; Köse T; Berdeli A
J Periodontol; 2007 Jul; 78(7):1256-63. PubMed ID: 17608581
[TBL] [Abstract][Full Text] [Related]
10. Tissue plasminogen activator and plasminogen activator inhibitor type 1 gene polymorphism in patients with gastric ulcer complicated with bleeding.
Kim HS; Hwang KY; Chung IK; Park SH; Lee MH; Kim SJ; Hong SY
J Korean Med Sci; 2003 Feb; 18(1):58-64. PubMed ID: 12589088
[TBL] [Abstract][Full Text] [Related]
11. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
Błasiak J; Smolarz B
Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
[TBL] [Abstract][Full Text] [Related]
12. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism.
Stegnar M; Uhrin P; Peternel P; Mavri A; Salobir-Pajnic B; Stare J; Binder BR
Thromb Haemost; 1998 May; 79(5):975-9. PubMed ID: 9609232
[TBL] [Abstract][Full Text] [Related]
13. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
[TBL] [Abstract][Full Text] [Related]
14. Investigation of Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case-control study.
Prabhudesai A; Shetty S; Ghosh K; Kulkarni B
Eur J Haematol; 2017 Sep; 99(3):249-254. PubMed ID: 28561456
[TBL] [Abstract][Full Text] [Related]
15. Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.
Xu F; Liu H; Sun Y
Ren Fail; 2016; 38(1):157-62. PubMed ID: 26616527
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism and prognosis of severely injured patients.
Menges T; Hermans PW; Little SG; Langefeld T; Böning O; Engel J; Sluijter M; de Groot R; Hempelmann G
Lancet; 2001 Apr; 357(9262):1096-7. PubMed ID: 11297964
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts.
Wiklund PG; Nilsson L; Ardnor SN; Eriksson P; Johansson L; Stegmayr B; Hamsten A; Holmberg D; Asplund K
Stroke; 2005 Aug; 36(8):1661-5. PubMed ID: 16020771
[TBL] [Abstract][Full Text] [Related]
18. 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke.
Bang CO; Park HK; Ahn MY; Shin HK; Hwang KY; Hong SY
Cerebrovasc Dis; 2001; 11(4):294-9. PubMed ID: 11385207
[TBL] [Abstract][Full Text] [Related]
19. Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.
Halamkova J; Kiss I; Pavlovsky Z; Tomasek J; Jarkovsky J; Cech Z; Bednarova D; Tucek S; Hanakova L; Moulis M; Zavrelova J; Man M; Benda P; Robek O; Kala Z; Penka M
Neoplasma; 2013; 60(2):151-9. PubMed ID: 23259783
[TBL] [Abstract][Full Text] [Related]
20. Genotype frequency of plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism in healthy Japanese males and its relation to PAI-1 levels.
Matsubara Y; Murata M; Isshiki I; Watanabe R; Zama T; Watanabe G; Watanabe K; Ikeda Y
Int J Hematol; 1999 Jan; 69(1):43-7. PubMed ID: 10641442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
